This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Non-small cell lung cancer (NSCLC)	Peroxisome proliferation-activated receptor- α (PPARA; PPAR α)	Mouse studies suggest PPARα agonists could help treat NSCLC. In transgenic mice that develop spontaneous NSCLC tumors, a PPARα ligand decreased tumor size, number and vascularization by decreasing the expression and activity of cytochrome P450 family 2 subfamily C polypeptide 44 (Cyp2c44) and levels of proangiogenic epoxyeicosatrienoic acids (EETs) compared with vehicle. Also in mice, PPARα-activating ligands including bezafibrate decreased primary tumor growth and metastasis of human NSCLC cells injected into the lung parenchyma. Next steps could include testing bezafibrate in additional models of NSCLC. Bezafibrate and other generic PPARα agonists are marketed to treat dyslipidemia. SciBX 7(3); doi:10.1038/scibx.2014.86 Published online Jan. 23, 2014	Patent and licensing status unavailable	Skrypnik, N. <i>et al. Cancer Res.</i>; published online Dec. 3, 2013; doi:10.1158/0008-5472.CAN-13-1928 Contact: Ambra Pozzi, Vanderbilt University School of Medicine, Nashville, Tenn. e-mail: ambra.pozzi@vanderbilt.edu